RA Capital Boosts Artiva Biotherapeutics Stake to 33.7% with $100M Offering Investment

summarizeSummary

RA Capital Management, a major institutional investor, significantly increased its stake in Artiva Biotherapeutics by purchasing nearly $100 million in common stock and pre-funded warrants as part of the company's recent public offering, raising its beneficial ownership to 33.7%.

check_boxKey Events

• Major Institutional Investment

  RA Capital Management, L.P. purchased approximately $100 million in common stock and pre-funded warrants on May 11, 2026.

• Increased Ownership Stake

  This transaction increases RA Capital's beneficial ownership to 33.7% of Artiva Biotherapeutics' common stock.

• Participation in Public Offering

  The purchase was made as part of the company's recent public offering, demonstrating strong institutional support following positive clinical data.

auto_awesomeAnalysis

This Schedule 13D/A confirms a substantial $100 million investment by RA Capital Management, a major institutional investor, into Artiva Biotherapeutics' recent public offering. This significant capital injection, which increases RA Capital's beneficial ownership to 33.7%, follows the company's positive initial clinical data for its lead program, AlloNK, and provides strong validation of its prospects. The investment represents a critical vote of confidence from a key stakeholder, especially after the company's recent capital raise.